We are searching data for your request:
Upon completion, a link will appear to access the found materials.
How should COVID-19 sufferers with cardiovascular problems be treated?
Proven anti-inflammatory therapies should be used in the treatment of COVID-19 patients who are at increased risk of cardiovascular problems or who have already developed these in the course of the disease.
A recent study by the Beijing Union Medical College & Chinese Academy of Medical Science concludes that cardiovascular anti-inflammatory therapies should be used to treat people with COVID-19 who suffer from cardiovascular problems or illnesses. The results of the study were published in the English language journal "Frontiers in Cardiovascular Medicine".
COVID-19 can cause inflammation-related cardiovascular problems
The researchers describe the different ways in which COVID-19 can cause serious inflammation-related cardiovascular problems. They also provide guidance on how to address these issues. Potential problems with drugs currently being administered to combat this virus are also highlighted.
How should people with severe COVID-19 be treated?
The research group was the first to extensively discuss the use of cardiovascular anti-inflammatory therapies for patients severely affected by COVID-19. The study provides guidelines for selecting specific cardiovascular anti-inflammatory therapies for people with COVID-19 that depend on the severity of the condition and the response of the affected person to the therapy. In addition, the researchers point out the known risks of treatments for the cardiovascular system that are currently being tested on people with COVID-19.
COVID-19: Risk to the Cardiovascular System?
The risk of pneumonia and shortness of breath in people with COVID-19 is already known, but there is increasing evidence of serious cardiovascular problems related to the disease. Inflammation plays an important role in the development and complications of cardiovascular diseases. The researchers observed that people with COVID-19 with stronger signs of an inflammatory reaction were more likely to experience severe cardiovascular events and were also at higher risk of death.
How does COVID-19 trigger cardiovascular problems?
The study identified a number of ways in which COVID-19 could trigger cardiovascular problems. The virus can directly infect the heart tissue and cause inflammation, aggravate existing cardiovascular problems or trigger an excessive immune response in the body, the researchers report.
Ongoing anti-inflammatory treatment aids recovery
By researching current promising treatments for COVID-19 and cardiovascular anti-inflammatory therapies, which have already been verified in clinical trials with positive results, the research group was able to highlight potentially effective treatments. In such a case, you are advised to carry out anti-inflammatory treatment to support recovery.
Be careful when using preclinical medication
However, the researchers warn against the use of new, pre-clinical drugs for the treatment of COVID-19 because of their unknown effectiveness and safety risks. In addition, caution should be exercised when using certain antiviral drugs, some of which are currently being clinically tested for the treatment of COVID-19.
These drugs can exacerbate cardiovascular problems
Some drugs, such as lopinavir / ritonavir, interferon-α, ribavirin, azithromycin, and hydroxychloroquine, that are currently used to treat COVID-19 can actually increase the risk of cardiovascular impairment, the research group explains. Given that these drugs, particularly the antiviral agents, can be essential in the clinical treatment of people with COVID-19, cardiovascular protection strategies are urgently needed to improve the overall prognosis. (as)
Author and source information
This text corresponds to the requirements of the medical literature, medical guidelines and current studies and has been checked by medical doctors.
- Lun Wang, Yang Zhang, Shuyang Zhang: Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy, in Frontiers in Cardiovascular Medicine (Published April 30, 2020), Frontiers in Cardiovascular Medicine